Yuanyuan Wu
- Toxicology top 5%
- Nephrology top 5%
- Acute Kidney Injury Research 10
- Chronic Kidney Disease and Diabetes 5
- Cancer Research top 10%
-
- RNA Interference and Gene Delivery 6
- RNA Research and Splicing 5
- Ubiquitin and proteasome pathways 4
- RNA modifications and cancer 4
- Pharmacology top 10%
-
- Erythropoietin and Anemia Treatment 5
-
- Cancer Immunotherapy and Biomarkers 4
- Co-authors
- Mingyao LiuZhengfang YiLi TangYufeng HuangMi TianBin YangRenfang MaoYihui Fan
- Cited by
- ToxicologyNephrologyCancer Research
- Journals
- Angewandte Chemie International Edition (1 paper)SHILAP Revista de lepidopterología (2 papers)Diabetes (1 paper)
- Partner nations
- ChinaUnited KingdomUnited States
In The Last Decade
Yuanyuan Wu
83 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 129
- Toxicology 59
- Nephrology 98
- Cancer Research 192
- Molecular Biology 669
- Pharmacology 74
Countries citing papers authored by Yuanyuan Wu
This map shows the geographic impact of Yuanyuan Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanyuan Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanyuan Wu more than expected).
Fields of papers citing papers by Yuanyuan Wu
This network shows the impact of papers produced by Yuanyuan Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanyuan Wu. The network helps show where Yuanyuan Wu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yuanyuan Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 1 | |
| 5 | 2025 | 0 | |
| 6 | 2025 | 5 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 27 | |
| 9 | 2024 | 4 | |
| 10 | 2024 | 1 | |
| 11 | 2023 | 6 | |
| 12 | 2023 | 1 | |
| 13 | 2023 | 17 | |
| 14 | 2023 | 16 | |
| 15 | 2023 | 8 | |
| 16 | 2023 | 5 | |
| 17 | 2023 | 5 | |
| 18 | HDL-Associated Lipoproteins: Potential Prognostic Biomarkers for Gram-Negative Sepsis | 2022 | 0 |
| 19 | 2021 | 16 | |
| 20 | 2018 | 1 |
About Yuanyuan Wu
Yuanyuan Wu is a scholar working on Nephrology, Acoustics and Ultrasonics and Toxicology, having authored 91 papers that have together received 1.4k indexed citations. Recurring topics across this work include Acute Kidney Injury Research (10 papers), RNA Interference and Gene Delivery (6 papers), Chronic Kidney Disease and Diabetes (5 papers), Erythropoietin and Anemia Treatment (5 papers), RNA Research and Splicing (5 papers), Ubiquitin and proteasome pathways (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and RNA modifications and cancer (4 papers). The work is most often cited by research in Toxicology (59 citations), Nephrology (98 citations) and Cancer Research (192 citations). Yuanyuan Wu has collaborated with scholars based in China, United Kingdom and United States. Frequent co-authors include Mingyao Liu, Zhengfang Yi, Li Tang, Yufeng Huang, Mi Tian, Bin Yang, Renfang Mao, Yihui Fan, Li Lai and Ulrika Johansson. Their work appears in journals such as Angewandte Chemie International Edition, SHILAP Revista de lepidopterología and Diabetes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.